COURTNEY STEPHENSON: Open Payments
NPI 1871374637 · NEWPORT NEWS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$439 in 12 payments from 7 companies in 2025. Trend: 2023 $123 · 2024 $371 · 2025 $439
Food & beverage: $439
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $118 |
| Supernus Pharmaceuticals, Inc. | 3 | $49 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Indivior Inc. | 1 | $22 |
| ABBVIE INC. | 1 | $16 |
Products named: INGREZZA, CAPLYTA, Qelbree, COBENFY, TRINTELLIX, SUBLOCADE, VRAYLAR.
Industry payments across VA — which companies pay providers there.
